Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Umbilical cord mesenchymal stem cells (SC) transplantation was a novel therapy for diabetes
mellitus, with less side effects and more advantages. Clinical trials had verified that good
metabolic control would be achieved when Liraglutide (GLP-1) was added to the conventional
therapies. The investigators hypothesized that the combined therapy of umbilical cord
mesenchymal stem cells transplantation and Liraglutide in type 2 diabetes mellitus will aid
the differentiation of stem cells into insulin-producing cells, improve the survival of
differentiated cells, protect the residual beta-cells and improve insulin secreting function,
so as to achieve a favorable glucose homeostasis.